Mylan Warning Letter Exposes Challenges In Valsartan Supply Chain Chemistry
Nitrosamines taint Mylan’s valsartan API solvent recovery, whether outsourced or in-house; firm mulls US FDA's request for ‘material systems review.’
You may also be interested in...
Mylan is pushing ahead with reforms that include wide-ranging product rationalization in the US, refocusing its commercial resources and cutting development and manufacturing costs. These reforms are intended to run prior to and concurrently with the group’s merger with Pfizer’s Upjohn unit to form Viatris.
How authorities plan to root out the carcinogenic impurities and what it means for other classes of medicines.
Lantech’s solvent recovery operations expected to meet US drug GMP requirements due to risk of carcinogens in blood pressure medications.